Biotech Analyst Picks Signal Major Upside Into 2026
Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026.
/ 2 items
Analysts highlight Alumis, Foghorn, and Lexeo as biotech stocks with strong clinical catalysts and significant upside potential into 2026.
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.